Actively Recruiting
cfMSC Stem Cell Therapy Targeting COPD
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-03-25
30
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.
CONDITIONS
Official Title
cfMSC Stem Cell Therapy Targeting COPD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand the study protocol and willingness to provide written informed consent
- Age 40-80 years old, male or female
- Diagnosed with moderate to severe COPD according to GOLD guidelines (GOLD I-III)
- Regular use of COPD conventional drugs for more than 3 months with stable condition for over 4 weeks
- Ineffective clinical treatment
- Life expectancy greater than 6 months
- Smoking cessation for at least six months, including non-smoking during treatment and follow-up periods
You will not qualify if you...
- Having other serious lung diseases such as asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, or pulmonary hypertension
- History of lung surgery (pneumonectomy, lung volume reduction surgery) or bronchial intervention surgery within 12 months
- Use of invasive or non-invasive mechanical ventilation within 4 weeks, or moderate to severe acute COPD exacerbation within 4 weeks
- Positive for HIV, HCV, or syphilis serology
- History of malignant tumors or currently undergoing treatment for cancer
- Autoimmune diseases requiring long-term glucocorticoids or immunosuppressants
- Poorly controlled diabetes (fasting blood glucose > 10.0 mmol/L) or severe metabolic diseases
- History of alcohol or drug abuse, or mental illness that prevents cooperation
- Pregnancy or breastfeeding
- Unable or unwilling to comply with study schedules or procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
L
Lung-Ji Chang, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here